Total Sales of ₹ 4728.42 crore at Janaushadhi Kendras in last 3 years

1. At a Glance

Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) is a flagship scheme of the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers for providing quality generic medicines at affordable prices through dedicated outlets called Jan Aushadhi Kendras (JAKs) [S1][S2].
UPSC relevance: maps to GS-II (Health, Welfare Schemes) and GS-III (Pharma sector, Economy); high prelims yield on numbers, implementing agency, and scheme architecture [S1].

PIB release dated 13 March 2026 reported total sales of ₹4,728.42 crore (MRP value) at JAKs during the last three financial years (FY 2022-23 to FY 2024-25) [S1].
18,646 JAKs operational across the country as on 28.02.2026 [S1].
Scheme evaluation by M/s Concept Research Media Tech and Info Solutions Pvt. Ltd. for FY 2023-24 submitted to the Department in July 2025 [S1].

Originally launched as Jan Aushadhi Campaign in November 2008 by the Department of Pharmaceuticals in collaboration with Central Pharma PSUs [S2].
Relaunched / rechristened as PMBJP in 2015–16, with a renewed push for nationwide expansion [S2].
Implementing agency: Pharmaceuticals & Medical Devices Bureau of India (PMBI) — an autonomous society under the Department of Pharmaceuticals [S2].
Milestone trajectory of JAK openings: 13,822 (2024) → 15,057 (Feb 2025) → 16,912 (June 2025) → 18,646 (Feb 2026) [S1][S2].

Nodal Ministry: Ministry of Chemicals & Fertilizers — Department of Pharmaceuticals [S1].
Implementing Agency: PMBI (autonomous society) [S2].
Scheme name: Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) [S1].
Outlet name: Jan Aushadhi Kendras (JAKs / PMBJKs) [S1].
Target: 25,000 JAKs by March 2027 [S2].
Year-wise MRP sales (₹ crore) [S1]:
FY 2022-23: 1,235.95
FY 2023-24: 1,470.00
FY 2024-25: 2,022.47
3-year total: 4,728.42
Operational JAKs: 18,646 as on 28.02.2026 [S1].

Economic: Generic medicines under PMBJP are priced 50–90% lower than branded equivalents; rising MRP sales (₹1,235→₹2,022 cr in two years) indicates deepening market penetration and consumer savings [S1].
Social / Welfare: Directly addresses out-of-pocket health expenditure — India's OOP share remains a key driver of healthcare-induced poverty; JAKs improve access to affordable essential drugs [S1].
Administrative: Delivery via a hub-and-spoke model — PMBI procures from approved manufacturers, distributes through warehouses, retails via franchisee-run JAKs; expansion depends on franchisee onboarding and state cooperation for premises [S2].
Governance / Evaluation: Independent third-party evaluation (Concept Research) submitted July 2025; recommendations forwarded for implementation — signals an evidence-based policy review cycle [S1].
Geographic Equity: State-wise distribution annexed to PIB note; gaps remain in NE states and remote districts — relevant for federal implementation analysis [S1].

March 2025: Jan Aushadhi Diwas 2025 week-long celebrations flagged off by Union Minister J.P. Nadda; 15,057 JAKs reported as on 28.02.2025 [S2].
June 2025: JAK count touched 16,912 [S2].
July 2025: Third-party evaluation report submitted to Department of Pharmaceuticals [S1].
February 2026: JAK count rises to 18,646; cumulative 3-year sales reach ₹4,728.42 crore [S1].

Scheme: Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) — launched originally in November 2008, rebranded as PMBJP [S2].
Implementing agency: PMBI (Pharmaceuticals & Medical Devices Bureau of India), an autonomous society under Department of Pharmaceuticals [S2].
Parent Ministry: Ministry of Chemicals & Fertilizers (NOT Ministry of Health & Family Welfare) [S1].
18,646 JAKs operational as on 28.02.2026 [S1].
3-year sales (FY22-23 to FY24-25): ₹4,728.42 crore at MRP value [S1].
FY 2024-25 sales: ₹2,022.47 crore [S1].
Target: 25,000 JAKs by March 2027 [S2].
Jan Aushadhi Diwas is observed on 7 March every year [S2].
Outlets sell medicines priced 50–90% cheaper than branded equivalents [S2].
Generic medicines under PMBJP must meet WHO-GMP quality standards (process compliance) [S2].

GS-II: Welfare schemes for vulnerable sections; issues relating to health.
GS-III: Indian Pharmaceutical Industry; Government Budgeting.
Question stems: 1. "Despite expanding outlet networks, the Pradhan Mantri Bhartiya Janaushadhi Pariyojana has yet to dent India's out-of-pocket health expenditure. Examine." 2. "Discuss the role of generic medicines in achieving Universal Health Coverage in India with reference to PMBJP." 3. "Evaluate the institutional architecture of PMBJP and suggest reforms for last-mile delivery."

Ayushman Bharat (PM-JAY) — complementary affordable healthcare pillar.
National Health Policy 2017 — UHC framework underpinning PMBJP.
National Pharmaceutical Pricing Authority (NPPA) — drug price control regulator.
Drugs (Prices Control) Order, 2013 — essential medicines pricing framework.
Department of Pharmaceuticals schemes — Bulk Drug Parks, PLI for Pharma.
WHO-GMP & Schedule M — manufacturing quality standards.
National List of Essential Medicines (NLEM) — basket overlap with PMBJP product list.
Out-of-pocket expenditure data — NSSO Health Surveys, National Health Accounts.

Wrongly attributing PMBJP to Ministry of Health & Family Welfare — it is under Chemicals & Fertilizers (Dept. of Pharmaceuticals) [S1].
Confusing PMBI (implementing agency, autonomous society) with NPPA (price regulator) or CDSCO (drug regulator) [S2].
Conflating original 2008 launch year with the 2015 PMBJP rebranding [S2].
Confusing Jan Aushadhi Diwas (7 March) with National Doctors' Day (1 July) or World Health Day (7 April).
Assuming JAKs sell only generics — they also stock surgical/nutraceutical items.

[S1] Total Sales of ₹4728.42 crore at Janaushadhi Kendras in last 3 years — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2239579 — (tier: 1)
[S2] PMBJP: A Journey Towards Affordable Healthcare / Jan Aushadhi Diwas 2025 / 16,912 JAKs update — https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=2067441 ; https://www.pib.gov.in/PressReleasePage.aspx?PRID=2149782 ; https://www.pib.gov.in/PressReleasePage.aspx?PRID=2114994 — (tier: 1)